<DOC>
	<DOCNO>NCT00149565</DOCNO>
	<brief_summary>* OBJECTIVES 1 . To investigate whether adjuvant IFN-α therapy delay reduce 2-5 year recurrence rate curatively resect HCC . 2 . To examine whether adjuvant IFN-α therapy prolong disease-free survival curatively resect HCC . 3 . To determine safety tolerance adjuvant IFN-α therapy postoperative HCC without cirrhosis . 4 . To investigate change activity HBV HCV postoperative HCC patient adjuvant IFN-α therapy . 5 . To correlate change viral status clinical outcome post-operative HCC patient adjuvant IFN-α therapy .</brief_summary>
	<brief_title>Phase Ⅲ Randomized Trial Postoperative Hepatocellular Carcinoma</brief_title>
	<detailed_description>1 . TREATMENT PLAN 1.1 Eligible patient randomize receive adjuvant IFN-α 53 wks 1.2 Administration IFN-α 1.21 IFN-α start randomization . 1.22 IFN-α administer subcutaneous injection bed time . 1.23 Escalation IFN-α dosage . 1.231 During first 2 day , 1 x 106 u/day give . 1.232 If tolerable , dose IFN-α escalate 3 x 106 u/day day 3 4 , 5 x 106 u/day day 5 . 1.24 After dose escalation , IFN-α 5 x 106 u/day give follow way 1.241 induction therapy : 5 time per week first 4 week , follow 1.242 maintenance therapy : 3 time per week additional 48 week . 1.25 Modification IFN-α dosage 1.251 In presence moderate adverse event ( list Appendix II ) require dose reduction 3 x 106 u/day . 1.2511 If moderate adverse event occur 3 x 106 u/day level , patient withdraw study ; 1.252 In presence severe adverse event ( list Appendix II ) , require immediate discontinuation therapy ; 1.2521 IFN-α discontinue return baseline moderate toxicity . Then IFN-α reinstituted dose level 3 x 106 u/day ; 1.2522 If moderate severe adverse event occur 3 x 106 u/day level , patient withdraw study . 1.253 Flare-up hepatitis activity , manifest increment serum transaminase per se indication dose modification ; 1.254 If symptoms/signs ( S/S ) hepatic decompensation occur presence ALT flare-up IFN-α therapy , drug hold . 1.2541 The presence two follow five criterion consider evidence hepatic decompensation : 1.25411 Presence ascites ; 1.25412 Presence hepatic encephalopathy ; 1.25413 hypoalbuminemia serum albumin &lt; 3 g/dl ; 1.25414 hyperbilirubinemia serum bilirubin &gt; 3 mg/dl ; 1.25415 Prolongation prothrombin time PT &gt; 2 sec base-line . 1.2542 Serial workup take rule presence predispose factor ( spontaneous bacterial peritonitis , constipation , electrolyte imbalance , ... ect ) cause S/S hepatic decompensation . If , start specific treatment . 1.2543 If S/S hepatic decompensation recover return serum ALT ≦1.5 time upper limit normal range , IFN-α restart level 3 x 106 u/day escalate 5 x 106 u/day within 1 week . 1.2544 If S/S hepatic decompensation recover persistent elevation serum ALT &gt; 1.5 time upper limit normal range , IFN-α give maintain level 3 x 106 u/day 3 time per week . 1.2545 After exclude specific etiology S/S hepatic decompensation persist longer 4 week , patient withdraw study . 1.2546 Recurrent episode hepatic decompensation consider severe adverse event manage list section 5.252 . 1.255 If symptoms/signs ( S/S ) hepatic decompensation occur absence ALT flare-up , patient manage list section 5.252 . 1.256 In presence severe bacterial infection : bacterial peritonitis , bacterial pneumonia , .. etc. , IFN-a hold resolution infection adequate antibiotic therapy . Then patient manage list section 5.252 . 1.26 Before IFN-α , necessary patient pretreated acetaminophen 500 - 1,000 mg , q 6 hour 4 dos , start 12 hour IFN-α administration alleviate associate flu-like symptom . 1.3 Adverse Drug Reaction ( ADR ) Reports 1.31 Any life threaten and/or unexpected serious ( grade 3 4 ) toxicity report within 48 hour principal investigator : Li-Tzong Chen M.D . Cancer Clinical Research Center , National Health Research Institutes , A191 Ward Veteran General Hospital Taipei , 201 , Shih-Pai Road , Sec 2 , Taipei 112 , Taiwan Tel:886-2-8712121-2737 ; Fax : 886-2-8716467 ; and/or Per-Jei Chen , M.D. , Ph.D. Department Internal Medicine , National Taiwan University Liver Disease Research Center , National Taiwan University Hospital . Tel : 886-2-3970800-7072 Fax : 886-2-3317624 . The initial contact make call Coordinate Center TCOG , 886-2-7852459 . A write report follow within 7 working day . 1.32 A write report submit within 7 work day describe life-threatening lethal ( grade 4 5 ) know reaction ( except grade 4 myelosuppression ) , grade 2 3 unknown reaction . The address submit ADR report : Coordinate Center TCOG , National Health Research Institutes Biomedical Science , Academia Sinica , Taipei , Taiwan . 1.33 Above toxicity grade accord ECOG toxicity criterion ( Appendix III ) 2.0 Evaluation The following test perform within 2 week initiation therapy ( baseline data ) repeat request follow initiation therapy . 2.1 Physical examination comprehensive history record bi-weekly induction period ( first month ) monthly maintenance therapy ( one year ) . After first year , patient follow bi-monthly . After 6 year , patient follow 3 monthly . 2.2 Complete blood count liver functional test ( bilirubin direct/indirect , AST/ALT alkaline phosphatase/gGT albumin AC sugar ) check bi-weekly induction period ( first month ) monthly maintenance therapy ( one year ) . After first year , patient follow bi-monthly . After 6 year , patient follow 3 monthly.. 2.3 Chest PA every 4 month one year every 6 month . 2.4 ECG history cardiac disease time symptom recurrence . 2.5 a-fetoprotein check monthly one year bi-monthly . After 6 year , patient follow 3 monthly . 2.6 Abdominal sonography every 2 month . After 6 year , patient follow 3 monthly . 2.7 Abdominal compute tomography perform every 12 month whenever abdominal sonography show suspicious recurrent lesion . 2.8 Any suspicious lesion find abdominal sonography and/or compute tomography undergo angiography sono-guided biopsy histological examination . 2.9 UGI endoscopy time UGI bleeding dyspepsia . [ CANCEAL ] 2.91 Preoperative endoscopy acceptable base-line data . [ CANCEAL ] 2.10 Bone scan time symptom suggest occurrence bony metastasis . 2.11 Serum HBV HCV status study collect bi-monthly . 2.12 HBeAg anti-HBe check every 4 month HBeAg ( + ) . After 6 year , patient follow 6 monthly . 2.13 HBsAg check every 6 month HBsAg ( + ) . 3.0 Off-study Criteria 3.1 Development serious medical condition make administration IFN-α life threaten . 3.11 Patients present S/S hepatic decompensation manage list section 5.2544 5.2545 . 3.12 list 5.2511 5.2522 . 3.2 Occurrence tumor recurrence . 3.3 Non-compliance patient protocol requirement . 3.4 Patient refusal therapy . 3.5 Patient death . 3.6 Interruption IFN-α therapy ＞4 week 4.0 Statistical Consideration 4.1 Sample size Review literatures show 2-year survival rate post-operative HCC 25 % 60 % [ 7-14 ] . We estimate adjuvant IFN-α improve 2-year survival rate 50 % 70 % . According method Casagrande et al . [ 129 ] , give 90 % power detect increase 20 % two-sided statistical significance test , 134 patient two treatment arm need . 4.2 Randomization Patients stratify two stratum : one HBsAg ( + ) , another HBsAg ( - ) anti-HCV ( + ) . Randomization patient control treatment group take within stratum . Balanced block size two strata randomization different . 4.3 Analysis 4.31 The primary objective follow : 4.311 To determine adjuvant IFN-α reduce delay occurrence curatively resect HCC . 4.312 To determine adjuvant IFN-α prolong disease-free survival ( DFS ) and/or overall survival ( OS ) curatively resect HCC . 4.313 To determine safety tolerance IFN-αin post-operative H.C.C patient . 4.314 To evaluate anti-viral activity IFN-α post-operative HCC patient . 4.32 DFS OS compute date randomization . 4.321 In analysis DFS , patient die without disease recurrence censor recurrence date death . 4.322 In analysis OS , event define death cause . 4.323 The survival distribution DFS OS estimate Kaplan Meier method [ 130 ] . 4 4.324 Statistical comparison DFS OS two treatment arm perform log-rank statistic [ 131 ] . 4.325 Cox proportional hazard model [ 132 ] use assess importance potential prognostic factor , well test significance treatment adjust factor . 4.33 Tumor size , Liver inflammation , viral status HBsAg . anti- HCVand - Patient 's Specific Factor : Performance status Age Sex Family history HCC liver disease . Esophageal varix Prior Hx esophageal varix bleed Serum ALT ( SGPT ) level Serum albumin level Pre-operative serum α-FP level - Underlying Liver Disease 's Specific Factors : HBsAg ( RIA ) HBeAg ( RIA ) anti-HBc anti-δ antibody anti-HCV antibody Severity underlie liver disease nontumor portion Concurrent management esophageal varix - Tumor 's Specific Factors : Presence capsule Tumor type Venous invasion Tumor size ( large multiple lesion ) Histological grade treat potential prognostic factor . 4.4 Interim Analysis The interim analysis conduct accord alpha spending function approach propose DeMets Lan ( 1994 ) provide flexibility time interim analysis . The a1 spending function , generate approximate O ’ Brien-Fleming boundary ( O ’ Brien Fleming , 1979 ) , use conservation termination early stage study . In addition , method B-value develop Lan Wittes ( 1988 ) , Li ( 1998 ) use monitor data compute conditional probability detect either positive negative treatment effect schedule end study give present status . The primary efficacy endpoint interim analysis time occurrence second primary tumor . The toxicity monitor constantly throughout study . The conduct interim analysis dissemination result interim analysis follow TCOG Data Safety Monitoring guideline confidentiality . The TCOG Data Safety Monitoring Committee review result interim analysis possible early termination trial .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Histologically proven hepatocellular carcinoma . 2 . HCC underwent curative resection within 6 week registration . 3 . Grossly , resection margin &gt; 1 cm . 4 . Patients must younger 70 yearold . 5 . Patients must performance status ECOG score &lt; 2 . 6 . Patients must adequate liver reservation adequate hemogram . 7 . PughChild ‘ Score &lt; 7 . 8 . The serum total bilirubin level &lt; 2 mg/dl . 9 . The prothrombin time &lt; 3 sec normal control . 10 . The platelet &gt; 10 x 104 / mm3 . 11 . The WBC &gt; 3,000 / mm3 . 12 . Patient must serum creatinine &lt; 1.5 mg/dl 13 . Cardiac function NYHA classification &lt; Grade II 14 . Known HBV HCV status . 15 . Signed informed consent . 1 . Patients noncurative resection eligible . 2 . Resected HCCs histologically positive margin eligible . 3 . HCCs radiological evidence portal vein thrombus eligible . 4 . Patients systemic disease require concurrent usage glucocorticosteroid immunosuppressant agent ( ) eligible . 5 . Patients advanced second primary malignancy eligible . 6 . Patients pregnacy breastfeed eligible . 7 . Patients severe cardiopulmonary disease eligible . 8 . Patients clinically significant psychiatric disorder eligible . 9 . Patients antineoplastic chemotherapeutic immunotherapeutic drug corticosteroid within 6 week commence protocol eligible .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2004</verification_date>
</DOC>